FI119355B - Pakastekuivatut ondansetronikoostumukset - Google Patents

Pakastekuivatut ondansetronikoostumukset Download PDF

Info

Publication number
FI119355B
FI119355B FI972167A FI972167A FI119355B FI 119355 B FI119355 B FI 119355B FI 972167 A FI972167 A FI 972167A FI 972167 A FI972167 A FI 972167A FI 119355 B FI119355 B FI 119355B
Authority
FI
Finland
Prior art keywords
ondansetron
freeze
free base
pharmaceutically acceptable
dried
Prior art date
Application number
FI972167A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972167L (fi
FI972167A0 (fi
Inventor
Ian Keith Winterborn
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI119355(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of FI972167L publication Critical patent/FI972167L/fi
Publication of FI972167A0 publication Critical patent/FI972167A0/fi
Application granted granted Critical
Publication of FI119355B publication Critical patent/FI119355B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Fertilizers (AREA)
FI972167A 1994-11-22 1997-05-21 Pakastekuivatut ondansetronikoostumukset FI119355B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions
GB9423511 1994-11-22
PCT/EP1995/004550 WO1996015785A1 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions
EP9504550 1995-11-20

Publications (3)

Publication Number Publication Date
FI972167L FI972167L (fi) 1997-05-21
FI972167A0 FI972167A0 (fi) 1997-05-21
FI119355B true FI119355B (fi) 2008-10-31

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972167A FI119355B (fi) 1994-11-22 1997-05-21 Pakastekuivatut ondansetronikoostumukset

Country Status (30)

Country Link
US (2) US5955488A (2)
EP (1) EP0793495B1 (2)
JP (1) JP3001264B2 (2)
KR (1) KR970706814A (2)
CN (1) CN1080118C (2)
AT (1) ATE193444T1 (2)
AU (1) AU704160B2 (2)
BE (1) BE1010250A3 (2)
BR (1) BR9509808A (2)
CY (1) CY2166B1 (2)
CZ (1) CZ285250B6 (2)
DE (1) DE69517332T2 (2)
DK (1) DK0793495T3 (2)
ES (1) ES2147309T3 (2)
FI (1) FI119355B (2)
FR (1) FR2727016B1 (2)
GB (2) GB9423511D0 (2)
GR (1) GR3033937T3 (2)
HU (1) HU226891B1 (2)
IL (1) IL116084A (2)
IT (1) IT1282352B1 (2)
MX (1) MX9703735A (2)
NO (1) NO306893B1 (2)
NZ (1) NZ296982A (2)
PL (1) PL181179B1 (2)
PT (1) PT793495E (2)
RU (1) RU2159614C2 (2)
TW (1) TW398976B (2)
WO (1) WO1996015785A1 (2)
ZA (1) ZA959821B (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
CA2392810A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
EP1339707A2 (en) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
PT1499623E (pt) * 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
MXPA04010845A (es) * 2002-04-30 2005-01-25 Biogal Gyogyszergyar Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
ATE522507T1 (de) 2003-10-10 2011-09-15 Synhton B V Montelukast in fester phase
ATE504588T1 (de) * 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
EP1758937B1 (en) * 2004-05-24 2009-09-02 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
AR057908A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast e intermediarios del mismo
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007107297A1 (en) * 2006-03-17 2007-09-27 Synthon B.V. Montelukast amantadine salt
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
CN101573106B (zh) * 2006-10-24 2013-07-24 赫尔辛医疗股份公司 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) * 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
RS65379B1 (sr) 2016-04-14 2024-04-30 Sensorion (+)-azasetron za upotrebu u lečenju poremećaja uha

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE24964T1 (de) * 1981-12-11 1987-01-15 Wyeth John & Brother Ltd Verfahren zur herstellung von festen formgegenstaenden.
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
ZA959821B (en) 1996-07-31
AU4173996A (en) 1996-06-17
GB9423511D0 (en) 1995-01-11
IT1282352B1 (it) 1998-03-20
GR3033937T3 (en) 2000-11-30
WO1996015785A1 (en) 1996-05-30
ATE193444T1 (de) 2000-06-15
AU704160B2 (en) 1999-04-15
JPH10508864A (ja) 1998-09-02
CN1080118C (zh) 2002-03-06
HUT77886A (hu) 1998-09-28
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
HK1009591A1 (en) 1999-06-04
ES2147309T3 (es) 2000-09-01
NO306893B1 (no) 2000-01-10
FI972167L (fi) 1997-05-21
NO972325L (no) 1997-05-22
IL116084A0 (en) 1996-01-31
KR970706814A (ko) 1997-12-01
GB2295318A (en) 1996-05-29
GB9523667D0 (en) 1996-01-24
FR2727016A1 (fr) 1996-05-24
CY2166B1 (en) 2002-08-23
DK0793495T3 (da) 2000-10-09
PT793495E (pt) 2000-10-31
US6063802A (en) 2000-05-16
GB2295318B (en) 1998-10-28
BR9509808A (pt) 1997-10-21
DE69517332D1 (de) 2000-07-06
DE69517332T2 (de) 2000-11-30
PL181179B1 (pl) 2001-06-29
FI972167A0 (fi) 1997-05-21
EP0793495A1 (en) 1997-09-10
MX9703735A (es) 1998-07-31
ITRM950762A0 (2) 1995-11-20
NO972325D0 (no) 1997-05-21
FR2727016B1 (fr) 1998-04-03
IL116084A (en) 2000-01-31
JP3001264B2 (ja) 2000-01-24
US5955488A (en) 1999-09-21
PL320295A1 (en) 1997-09-15
CZ154997A3 (en) 1997-10-15
TW398976B (en) 2000-07-21
NZ296982A (en) 1998-06-26
HU226891B1 (en) 2010-01-28
RU2159614C2 (ru) 2000-11-27
EP0793495B1 (en) 2000-05-31
CZ285250B6 (cs) 1999-06-16
BE1010250A3 (fr) 1998-04-07

Similar Documents

Publication Publication Date Title
FI119355B (fi) Pakastekuivatut ondansetronikoostumukset
KR100292124B1 (ko) 온단세트론을포함하는경구조성물
EP0664697B1 (en) Ranitidine chewable tablets
US20050084530A1 (en) Rapid acting freeze dried oral pharmaceutical composition for treating migraine
JP2002543160A (ja) 医薬処方
CA2205600C (en) Freeze-dried ondansetron compositions
JPH10511637A (ja) ヒスタミンｈ▲下２▼−アンタゴニストの吸収を増強するためのグルコースのようなパラセルラー吸収エンハンサーの使用
MXPA97003734A (en) Oral compositions containing ondanset
JP2006507266A (ja) 性的機能不全を処置するための組成物および方法
JPH10502331A (ja) 酸分泌過多による軽胃腸障害を治療する低投与量ラニチジン組成物

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119355

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: GLAXOSMITHKLINE INC.

MA Patent expired